A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

NCT01977651 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

424

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Enzalutamide

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]